Spark New Zealand Ltd

SPK Details
· Extending the funds flexibility: Spark New Zealand Ltd (ASX: SPK) established a revolving facility of NZ$125 million with Westpac which would mature on 30^th November 2020. Accordingly, the stock rose over 4.23% on November 30, 2016.

· Offsetting core fixed line voice and legacy data business by focusing on mobile and Platform IT:  The group is focusing on growing business like mobile and platform IT to offset the pressure coming from fixed line voice and legacy data. Even though the group revenues fell to $3.497 billion, overall operating revenues and other gains rose 2.5% on a like-for-like basis driven by changes to Chorus charges coupled with acquisitions. For fiscal year of 2016, Spark was able to generate over $1.134 billion revenues which is an increase of 11.3% on a year over year basis. The group’s broadband revenues rose 5.4% driven by the higher-value plans and better digital services like Lightbox and Morepork, a smart living solution. The group’s media division, Sky is positioning via premium sports content.

· Recommendation: Having a solid dividend yield, we give a “Hold” recommendation on the stock at the current price of – $ 3.45

Zelda Therapeutics Ltd

ZLD Details
· Encouraging results from Pre-Clinical studies of THC-rich medical cannabis formulation: Zelda Therapeutics Ltd (ASX: ZLD) stock surged over 34.8% on November 30, 2016 as their initial pre-clinical studies of THC-rich medical cannabis formulation showed anti-cancer effects. The group’s formulation of THC-rich oil showed major potential at reducing tumor growth than pure THC and has the similar potential as Lapatanib in reducing tumor growth. These positive results offer support to the group’s ongoing program for evaluating the potential whether their THC-rich medical cannabis formulations can be anti-cancer therapeutics.

· Recommendation: We believe the stock is placed at slightly higher levels given the prospects as of now. We give an “Expensive” recommendation on the stock at the current price of – $ 0.031

Comparison of Zelda formulation to standard care (Source: Company Reports)

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd currently hold positions in:  BHP, BKY, KCN, PDN, and RIO. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.